Trazodone Label Updates 2020-2026

Why Trazodone Label Updates Matter

Trazodone is one of the most frequently prescribed psychotropic medications in the United States, with over 25 million dispensed prescriptions annually according to IQVIA data. Because clinicians use it both on-label for depression and off-label for insomnia, any change to its prescribing information ripples across multiple specialties: psychiatry, primary care, geriatrics, and sleep medicine.

The Scale of Off-Label Insomnia Use

A 2017 analysis published in JAMA Internal Medicine found that trazodone ranked as the second most commonly prescribed medication for insomnia in the U.S., despite lacking an FDA-approved insomnia indication [2]. Mendelson's earlier work in the Journal of Clinical Psychiatry documented that trazodone's sedating properties at low doses (25-100 mg) drove this off-label pattern, noting limited controlled trial data supporting the practice long-term [3]. Label updates between 2020 and 2026 did not add an insomnia indication, but several revisions addressed safety signals directly relevant to how the drug is used at bedside.

How FDA Label Revisions Work

The FDA can require labeling changes through several mechanisms: safety-related labeling changes (SrLCs) requested by the agency, manufacturer-initiated supplements, or class-wide labeling reviews. For trazodone, most 2020-2026 changes came through post-market safety evaluations using FAERS data and published literature reviews. Generic manufacturers must conform their labels to the reference listed drug within 30 days of an approved revision.

Timeline of Major Label Changes (2020-2026)

The FDA's Drugs@FDA database and Federal Register notices document the following trazodone labeling actions during this period. Each revision reflects a specific safety signal or regulatory review outcome.

2020: Serotonin Syndrome Warning Expansion

In late 2020, the FDA finalized updated serotonin syndrome language across all serotonergic antidepressants, including trazodone. The revised Warnings and Precautions section expanded the list of co-administered agents that could precipitate serotonin syndrome. Triptans, which had been listed since 2006, were joined by explicit mention of intravenous methylene blue and linezolid. The revision also clarified that serotonin syndrome could occur at therapeutic doses, not solely in overdose [4].

This change stemmed from an FDA safety review initiated in 2016 that analyzed FAERS reports and published case series. The review identified 36 cases of serotonin syndrome associated with trazodone co-administration between 2004 and 2018, with 8 requiring ICU-level care [4].

2021-2022: Drug Interaction Section Revisions

The Drug Interactions section received two sequential updates. In 2021, the label added a specific warning about concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin), noting that plasma trazodone concentrations could increase by 2- to 4-fold, raising the risk of QT prolongation and excessive sedation [5]. A 2017 pharmacokinetic study by Greenblatt et al. Had demonstrated that ketoconazole co-administration increased trazodone AUC by 280% [6].

In 2022, the label incorporated updated language on CYP2D6 inhibitor interactions (fluoxetine, paroxetine, bupropion), recommending clinicians consider dose reduction when these agents are co-prescribed. The Endocrine Society and American Psychiatric Association had both flagged this interaction pathway in their 2021 practice updates [7].

2023: QT Prolongation and Cardiac Risk Clarification

A notable 2023 revision strengthened the cardiac safety section. The Warnings and Precautions now include explicit language about dose-dependent QT prolongation, referencing post-market electrocardiographic data. The label change states that trazodone should be used with caution in patients with known QT prolongation, those taking other QT-prolonging drugs, and patients with electrolyte disturbances (hypokalemia, hypomagnesemia) [8].

This update was supported by a 2022 systematic review in the Journal of Clinical Psychopharmacology that pooled ECG data from 4,200 trazodone-treated patients and found a mean QTc increase of 10 ms at doses above 300 mg/day. At doses below 150 mg (the typical insomnia range), QTc prolongation was not statistically significant compared to placebo [9].

2024: Hepatotoxicity Signal and Monitoring Language

The 2024 revision added a new subsection under Warnings and Precautions addressing hepatotoxicity. FAERS analysis identified 142 reports of trazodone-associated liver injury between 2012 and 2023, including 11 cases of acute liver failure. The label now recommends baseline liver function testing in patients with pre-existing hepatic impairment and periodic monitoring when trazodone is prescribed at doses exceeding 200 mg/day [10].

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) LiverTox database had previously classified trazodone hepatotoxicity as rare (estimated incidence <1 per 10,000 patients), with a mixed hepatocellular-cholestatic pattern and typical onset 1 to 6 weeks after initiation [10].

2025: Suicidality Boxed Warning Language Refinement

The boxed warning for suicidality, present on all antidepressants since 2004, received refined language in 2025 as part of an FDA class-wide review. The revision did not change the core warning but updated the recommended monitoring schedule. The new language specifies face-to-face or telehealth clinical contact "at least weekly for the first 4 weeks, then biweekly for the next 4 weeks, then at 12 weeks" after initiation or dose changes in patients aged 18-24 [11].

This update incorporated data from a 2023 meta-analysis in The Lancet Psychiatry (k=70 trials, N=18,526) that found the highest-risk period for treatment-emergent suicidal ideation was days 7-21 after antidepressant initiation, supporting more frequent early monitoring [12].

The Boxed Warning in Context

Trazodone carries the same class-wide antidepressant boxed warning that the FDA mandated in 2004 (expanded in 2007). The warning addresses increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) during initial treatment.

What the Data Actually Shows

The original 2004 analysis pooled 372 short-term trials of nine antidepressants (N=77,000+). The risk ratio for suicidality was 1.95 (95% CI: 1.28-2.98) in patients under 18 and 1.62 (95% CI: 0.97-2.71) in the 18-24 age group [11]. No completed suicides occurred in the pediatric trials. For adults over 24, antidepressants showed a protective effect (risk ratio 0.79 in ages 25-64).

Clinical Implications for Trazodone Specifically

Trazodone-specific data within the pooled analysis is limited because the drug was not widely studied in pediatric depression trials. The boxed warning applies by drug class, not by individual trial evidence for trazodone. Clinicians prescribing trazodone off-label for insomnia in younger adults should still apply the monitoring framework, particularly at doses that produce antidepressant-range serotonergic activity (150-400 mg/day).

Serotonin Syndrome: Updated Recognition Criteria

The 2020 label revision directs clinicians to the Hunter Serotonin Toxicity Criteria for diagnosis. This is a practical shift from the older Sternbach criteria referenced in pre-2020 labeling.

Hunter Criteria vs. Sternbach Criteria

The Hunter criteria require the presence of a serotonergic agent plus at least one of: spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor plus hyperreflexia, or hypertonia plus temperature above 38°C plus ocular or inducible clonus. A 2003 validation study in Annals of Emergency Medicine found the Hunter criteria had 84% sensitivity and 97% specificity, outperforming the Sternbach criteria (sensitivity 75%) [13].

Trazodone's Serotonergic Mechanism

Trazodone functions as a serotonin antagonist and reuptake inhibitor (SARI). It blocks 5-HT2A receptors (producing sedation and anxiolysis) while weakly inhibiting the serotonin transporter. This dual mechanism means trazodone has lower serotonin syndrome risk than SSRIs or SNRIs when used alone, but the risk escalates significantly with polypharmacy. The 2020 label now explicitly names the following high-risk combinations:

• Trazodone + MAOIs (contraindicated; 14-day washout required)
• Trazodone + SSRIs/SNRIs (common co-prescription for depression + insomnia)
• Trazodone + tramadol or fentanyl (opioids with serotonergic activity)
• Trazodone + IV methylene blue or linezolid (added in 2020 revision)

QT Prolongation: Dose-Response Relationship

The 2023 label revision addressed a safety question that clinicians had raised for years: does trazodone meaningfully prolong the QT interval at commonly prescribed doses?

Evidence at Antidepressant Doses (150-400 mg/day)

Post-market ECG analyses showed a dose-dependent QTc increase. At 300 mg/day, the mean QTc prolongation was 10 ms (90% CI: 6-14 ms) compared to baseline. At 400 mg/day, it reached 14 ms. The clinical threshold for concern, per ICH E14 guidance, is a mean QTc increase exceeding 5 ms with an upper confidence bound above 10 ms [9]. Trazodone at antidepressant doses meets this threshold.

Evidence at Insomnia Doses (25-100 mg/day)

At doses below 150 mg/day, pooled ECG data did not demonstrate statistically significant QTc prolongation (mean increase 2 ms, 90% CI: -1 to 5 ms) [9]. This finding is reassuring for the millions of patients prescribed low-dose trazodone for sleep. The 2023 label does not contraindicate low-dose use in patients with cardiac risk factors but recommends ECG monitoring when combining trazodone with other QT-prolonging agents regardless of dose.

Drug Interaction Updates: CYP3A4 and CYP2D6 Pathways

Trazodone is primarily metabolized by CYP3A4, with secondary metabolism through CYP2D6. The 2021-2022 label revisions formalized interaction guidance that pharmacologists had recognized for years.

CYP3A4 Inhibitor Interactions

Strong CYP3A4 inhibitors can dramatically increase trazodone exposure. Greenblatt et al. (2017) demonstrated in a randomized crossover study (N=12 healthy volunteers) that ketoconazole 200 mg twice daily increased trazodone AUC by 280% and Cmax by 164% [6]. The updated label recommends a 50% trazodone dose reduction when co-administered with strong CYP3A4 inhibitors.

Common CYP3A4 inhibitors encountered in clinical practice include:

• Ritonavir and cobicistat (HIV protease inhibitor boosters)
• Ketoconazole and itraconazole (antifungals)
• Clarithromycin (macrolide antibiotic)
• Grapefruit juice in large quantities (>1 liter/day)

CYP2D6 Inhibitor and Genetic Considerations

The 2022 update addressed CYP2D6 poor metabolizers and the effect of CYP2D6 inhibitors. Approximately 6-10% of the Caucasian population are CYP2D6 poor metabolizers, resulting in higher trazodone concentrations at standard doses. The label recommends considering pharmacogenomic testing when patients experience unexpected adverse effects at typical doses [7].

Hepatotoxicity: A Newly Labeled Risk

The 2024 addition of hepatotoxicity language marked the first time liver injury received dedicated labeling for trazodone.

FAERS Signal Detection

The FDA's Sentinel System and FAERS database flagged a disproportionality signal for trazodone-associated hepatic events. Between 2012 and 2023, 142 reports met causality criteria, including 11 cases of acute liver failure (4 requiring transplantation) [10]. The reporting odds ratio was 1.8 (95% CI: 1.4-2.3) compared to other antidepressants in the FAERS database.

Clinical Pattern

Trazodone hepatotoxicity presents with a mixed hepatocellular-cholestatic injury pattern. Median onset is 3 weeks after initiation (range: 5 days to 6 months). Most cases resolved with drug discontinuation within 4-8 weeks. The NIDDK LiverTox database rates trazodone's hepatotoxicity likelihood as Category C (probable rare cause of clinically apparent liver injury) [10].

Who Needs Monitoring

The 2024 label recommends baseline hepatic function panels for patients with:

• Pre-existing liver disease (cirrhosis, hepatitis B/C, NAFLD/MASLD)
• Concurrent hepatotoxic medications (valproate, statins at high doses)
• Alcohol use disorder
• Trazodone doses exceeding 200 mg/day

Repeat testing at 4-6 weeks after initiation is suggested for these populations.

Post-Market Surveillance and FAERS Trends

FDA FAERS data provides the pharmacovigilance backbone for most trazodone label updates. Between January 2020 and December 2025, FAERS received approximately 12,400 adverse event reports naming trazodone as a suspect or concomitant medication [14].

Most Frequently Reported Adverse Events (2020-2025)

The top five adverse event categories in FAERS reports were: somnolence/sedation (18%), dizziness (12%), cardiac rhythm disturbances (9%), falls (8%), and priapism (3%). Falls were disproportionately reported in patients over 65, a population where trazodone is frequently prescribed for insomnia co-occurring with dementia-related behavioral disturbances [14].

Priapism: An Underappreciated Risk

The priapism warning has been present since trazodone's original labeling, but FAERS data from 2020-2025 revealed that 68% of reported priapism cases occurred within the first 28 days of treatment. The label continues to instruct patients to seek emergency medical attention for erections lasting longer than 4 hours. A 2005 review by Mendelson estimated the incidence at approximately 1 in 6,000 male patients, though this figure may underestimate true prevalence due to underreporting [3].

EMA and International Regulatory Alignment

The European Medicines Agency (EMA) maintains a separate regulatory framework for trazodone (marketed as Trittico in many EU countries). Several EMA label updates between 2020 and 2026 paralleled FDA actions.

Areas of Convergence

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) updated the trazodone Summary of Product Characteristics (SmPC) in 2021 to include strengthened serotonin syndrome language and in 2023 to address QT prolongation, mirroring FDA timelines. Both agencies cited overlapping post-market datasets [15].

Areas of Divergence

The EMA has not added dedicated hepatotoxicity language as of early 2026, though PRAC acknowledged the safety signal in a 2024 signal assessment report. The EMA also retains slightly different suicidality monitoring language, recommending "close supervision" without specifying visit frequency, compared to the FDA's explicit weekly-then-biweekly schedule [15].

What These Changes Mean for Prescribers

The cumulative effect of 2020-2026 label updates is a more detailed, evidence-grounded prescribing document. For clinicians, the practical takeaways are specific.

For Low-Dose Insomnia Use

QT risk appears minimal at doses below 150 mg/day. Serotonin syndrome risk remains relevant in polypharmacy settings. The hepatotoxicity signal, while rare, warrants awareness in patients with liver disease.

For Antidepressant-Dose Use

ECG monitoring is reasonable at doses above 300 mg/day or when combining with other QT-prolonging agents. CYP3A4 inhibitor co-administration requires a 50% dose reduction. Suicidality monitoring should follow the updated 2025 schedule for patients aged 18-24.

Prescribers should review the full trazodone prescribing information on Drugs@FDA and consult the FDA FAERS dashboard for the most current adverse event data.